NASDAQ:CYTKCytokinetics Stock Price, Forecast & News

Cytokinetics' stock was trading at $12.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CYTK stock has increased by 112.0% and is now trading at $25.50. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 7 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cytokinetics.

Cytokinetics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Cytokinetics.

Cytokinetics, Inc. (NASDAQ:CYTK) announced its earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.50) by $0.16. The biopharmaceutical company had revenue of $3.83 million for the quarter, compared to the consensus estimate of $4.92 million. View Cytokinetics' earnings history.

8 equities research analysts have issued twelve-month price objectives for Cytokinetics' shares. Their forecasts range from $20.00 to $39.00. On average, they anticipate Cytokinetics' share price to reach $28.75 in the next year. This suggests a possible upside of 12.7% from the stock's current price. View analysts' price targets for Cytokinetics.

News articles about CYTK stock have been trending neutral on Saturday, according to InfoTrie. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cytokinetics earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Cytokinetics.

Cytokinetics saw a drop in short interest in June. As of June 30th, there was short interest totaling 7,720,000 shares, a drop of 6.3% from the June 15th total of 8,240,000 shares. Based on an average trading volume of 867,200 shares, the short-interest ratio is currently 8.9 days. Approximately 14.2% of the company's shares are sold short. View Cytokinetics' Current Options Chain.

Some companies that are related to Cytokinetics include Bausch Health Companies (BHC), PPD (SDGR), Jazz Pharmaceuticals (JAZZ), Ultragenyx Pharmaceutical (RARE), Zai Lab (ZLAB), Reata Pharmaceuticals (RETA), United Therapeutics (UTHR), Mirati Therapeutics (MRTX), Legend Biotech (LEGN), Emergent Biosolutions (EBS), Arrowhead Pharmaceuticals (ARWR), Biohaven Pharmaceutical (BHVN), Nektar Therapeutics (NKTR), Myokardia (MYOK) and Blueprint Medicines (BPMC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (AMGN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Geron (GERN), TherapeuticsMD (TXMD), Gilead Sciences (GILD) and Immunomedics (IMMU).

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Cytokinetics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.02%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Fady Ibraham Malik, Robert I Blum, Sandford D Smith, Santo J Costa, Value Fund L P Biotechnology and Wendall Wierenga. View institutional ownership trends for Cytokinetics.

CYTK stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have sold Cytokinetics company stock in the last year include Bvf Partners L P/Il, Fady Ibraham Malik, Robert I Blum, Sandford D Smith, Santo J Costa, and Wendall Wierenga. View insider buying and selling activity for Cytokinetics.

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CYTK stock can currently be purchased for approximately $25.50.

Cytokinetics has a market capitalization of $1.52 billion and generates $26.87 million in revenue each year. The biopharmaceutical company earns $-121,690,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Cytokinetics employs 130 workers across the globe.

The official website for Cytokinetics is www.cytokinetics.com.

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]